Objective: Chest pain is a common finding in patients with hypertrophic cardiomyopathy and can be observed in 40% to 50% of all patients. However, the pathogenesis of these ischemia-like symptoms is still unclear.

Methods: Twenty-two patients with hypertrophic cardiomyopathy and 15 controls underwent positron emission tomography for evaluation of regional myocardial perfusion and coronary flow reserve (hyperemic/baseline myocardial blood flow). Myocardial perfusion (mL/min/g) was measured using $[^{15}N]$ammonia at rest and during hyperemia with dipyridamole (0.56 mg/kg intravenously). Regional coronary flow reserve was assessed in 3 planes (apical, midventricular, basal) in 4 regions (septal, anterior, lateral, inferior). Patients were divided into 2 groups: group 1 consisted of 11 patients treated with surgical myectomy (age 56 ± 10 years) and group 2 consisted of 11 patients treated medically (age 53 ± 13 years).

Results: Mean global coronary flow reserve was 3.87 ± 0.92 in controls but 2.31 ± 0.40 in operated ($P < .001$ vs controls) and 1.76 ± 0.58 in medically treated patients ($P < .001$ vs controls, $P < .05$ vs operated). Similarly, septal coronary flow reserve was 4.19 ± 1.22 in controls but significantly reduced in operated patients (2.26 ± 0.48, $P < .001$ vs controls) and in medically treated patients (1.76 ± 0.58; $P < .001$ vs controls). However, septal flow reserve was significantly higher in operated patients than in patients with medically treated hypertrophic cardiomyopathy (+37%, $P < .05$), mainly due to a reduced resting myocardial perfusion.

Conclusions: Global and regional myocardial perfusion is reduced in patients with hypertrophic cardiomyopathy. However, myectomy may have a beneficial effect on septal perfusion and flow reserve. Thus, ischemia seems to play an important role in the symptomatology and pathophysiology of hypertrophic cardiomyopathy.

Hypertrophic cardiomyopathy (HCM) is a progressive disease with significant morbidity and mortality. Sudden unexpected death can be the first clinical manifestation of HCM and is the most devastating feature in the natural history of the disease. Occurrence of sudden cardiac death has been reported to be about 2% to 3% per year. $^1$ Approximately 60% to 70% of all patients with this disease die suddenly. Hemodynamic and electrophysiological studies in patients with HCM
have demonstrated several potential mechanisms for cardiac arrest or sudden death, including atrial arrhythmias associated with hypotension, bradycardia, and ventricular tachyarrhythmias, all of which can be exacerbated in the presence of left ventricular outflow tract obstruction or myocardial ischemia.2 Chest pain and signs of ischemia have been found to occur frequently.3 In HCM, similarly to severe secondary left ventricular hypertrophy, the metabolic demands of the increased left ventricular muscle mass cannot be met by a parallel increase in coronary luminal area.4 As a consequence of left ventricular hypertrophy, large epicardial coronary arteries are dilated, which leads to a reduced coronary vasodilator capacity5 and impaired flow reserve, resulting in an underperfusion during high demand conditions. The pathophysiology of myocardial perfusion in the HCM muscle area may be crucial for sudden cardiac death. Camici and coworkers6 reported an impaired coronary vasodilator reserve in both hypertrophied and nonhypertrophied regions of the left ventricle in HCM using positron emission tomography (PET), suggesting that ischemia may result from abnormalities of the coronary microcirculation. This is supported by postmortem2 and ex vivo7 analyses of HCM hearts where an abnormal thickening of the arteriolar wall and a decreased capillary density were found with progressive left ventricular hypertrophy.

Surgical management of HCM was first introduced by Cleland,8 who performed myotomy/myectomy of the hypertrophied septum using a transventricular approach. This technique was later adapted by others, and transaortic myectomy has become the treatment of choice for severely symptomatic patients with large outflow tract pressure gradients,9 which is a strong, independent predictor of progression to severe symptoms of heart failure and of death.10 Septal myectomy has been associated with an improvement in symptoms and an increase in exercise capacity, but whether it prevents septal ischemia by changing the perfusion pattern, and thus prolongs life, remains unclear.

The aim of the present study was to evaluate the influence of surgical myectomy on regional and global perfusion and to compare it to medically treated patients with HCM.

Methods
The study protocol was approved by the local ethics committee. The investigation conforms with the principle outlines in the Declaration of Helsinki. Each volunteer signed the informed consent form after the investigative nature of the study and its risks and merits had been carefully explained.

Study Population
A total of 22 patients with HCM were studied: 11 had undergone surgical myectomy (HCM op) 13 ± 5 years ago and 11 were medically treated (HCM med). Mean age was 56 ± 10 and 54 ± 13 years for operated patients and medically treated patients, respectively (P = NS). All medication was withdrawn 48 hours before the study. Six patients operated for HCM were treated with the calcium channel blocker verapamil and 3 with beta-blockers, whereas 3 of the medically treated patients were on each of these treatment options. In the medically treated group angina pectoris was present in 4, dyspnea in 5, and syncope in 3 patients. Dyspnea was reported in 5 operated patients during the postoperative follow-up. Prior to myectomy, however, all patients were symptomat-ic with either dyspnea (7 patients) or angina (7 patients) or syncope (8 patients) or a combination of these. The policy for conservative (medical) or surgical treatment remained unchanged at our hospital over the years of the study and was as follows. (1) Patients with a significant pressure gradient (>25 but ≤50 mm Hg) or typical symptoms that responded well to medical therapy were followed on medical treatment. (2) Patients were treated surgically if they had a resting pressure gradient of more than 50 mm Hg or a pressure gradient after postextrasystolic potentiation of more than 100 mm Hg or when clinical symptoms were present that did not respond or insufficiently responded to medical therapy. The same operator performed surgical myectomy in all patients by the transaortic/transventricular approach throughout the years.

Fifteen volunteers without cardiovascular disease served as controls (mean age of 34 ± 14 years; P < .01 vs HCM). None of the controls had a history of cardiovascular disease or risk factors. Entrance criteria included normal heart rate, blood pressure, normal resting electrocardiogram (ECG), and low clinical probability for coronary artery disease.11

The study was performed after overnight fasting. All subjects were carefully instructed to refrain from caffeine intake within 24 hours before the study.

Study Protocol
All volunteers were injected with 700 to 900 MBq [13 N]ammonia into a peripheral vein by bolus technique while acquisition of the serial transaxial tomographic images of the heart was started. The 20-minutes acquisition scan was followed by a 20-minute transmission scan for photon attenuation correction using external 68 Ge sources. This was followed by an intravenous infusion of dipyrindamole (140 μg/kg/min) over 4 minutes and a second bolus of 700 MBq [13 N]ammonia, which was injected 8 minutes after starting of the dipyrindamole infusion.

PET Scanning
All images were acquired on a General Electric positron emission tomograph, which records 35 image planes simultaneously. The axial field of view is 14.5 cm. A 30-minute blank scan was recorded as part of the daily routine procedures. Correct positioning of the volunteer’s heart within the axial field of view of the tomograph was ascertained on a 4-minute rectilinear transmission scan. Starting with the intravenous administration of [13 N]ammonia, 12 frames of 10 seconds each, 4 of 30 seconds, 1 of 60 seconds, and 2 of 300 seconds were recorded.

Data Analysis
The transaxially acquired images were reoriented to obtain short-axis images of the heart. A basal, a midventricular, and an apical slice were then chosen for further analysis. In each slice a region
of interest (ROI) was placed within the septal, anterior, lateral, and inferior segments.

**Estimates of Myocardial Blood Flow**

A spherical ROI was placed into the blood pool of the left ventricle. Myocardial and blood pool time-activity curves were generated from the dynamic frames and corrected for radioisotope decay. Myocardial blood flow (MBF) was estimated by model fitting of the blood pool and myocardial time-activity curves using a 3-compartment model. The corrections for partial volume and spillover (both accounting for the resolution distortion) have been performed using the method described and validated by Hutchins and coworkers. Briefly, the ROI is chosen to contain only myocardial tissue and blood and, thus, the relation between the measured PET counts in a region (CPET) and the true counts in myocardium (Cm) and arterial blood (Ca) is modeled as follows: CPET(t) = FhCa(t) + (1 − Fh)Cm(t). Fh is the fractional contribution of the blood pool to measured PET counts in a region and is dependent on the placement of the region, the resolution of the camera, and movement of the myocardium. Because the contribution of myocardium to total regional counts decreases with increasing blood pool fraction, cm is multiplied with (1 − Fh). Fh is estimated together with the other kinetic tissue parameters using least-squares fitting.

Coronary flow reserve (CFR) was calculated as the ratio of hyperemic to resting MBF for global and regional MBF values. To account for the variability of coronary driving pressure, coronary resistance (mm Hg/mL/min/g) was also calculated as the ratio of mean arterial pressure to MBF as previously reported.

**Statistical Analysis**

Statistical comparison of hemodynamic data, MBF, and CFR were carried out by a 1-way analysis of variance for repeated measurements. When the analysis was significant, the Scheffé procedure was applied. Data are reported as mean values ± standard deviation (SD) if not otherwise stated.

**Results**

All procedures were well tolerated apart from the common side effects caused by dipyridamole. None of the subjects experienced any ECG changes during the procedure.

**Echocardiographic Data**

In the operated patients preoperative gradients were 63 ± 15 mm Hg. The postoperative data (Table 1) show that in operated patients compared with medically treated patients there was a tendency to smaller interventricular septal wall thickness and lower fractional shortening and pressure gradient, which fell short of statistical significance. Left ventricular end-diastolic chamber diameter did not differ between the 2 groups (Table 1). Six of the medically treated patients had no outflow tract obstruction and 5 had a gradient of 26 ± 17 mm Hg (63 ± 16 mm Hg during Valsalva maneuver).

<table>
<thead>
<tr>
<th>TABLE 1. Echocardiographic data</th>
</tr>
</thead>
<tbody>
<tr>
<td>HCM op</td>
</tr>
<tr>
<td>IVS (mm)</td>
</tr>
<tr>
<td>PW (mm)</td>
</tr>
<tr>
<td>LVEDD (mm)</td>
</tr>
<tr>
<td>FS (%)</td>
</tr>
<tr>
<td>SAM (yes/no)</td>
</tr>
<tr>
<td>ΔP (mm Hg)</td>
</tr>
<tr>
<td>HR</td>
</tr>
<tr>
<td>SBP</td>
</tr>
<tr>
<td>DBP</td>
</tr>
<tr>
<td>RPP</td>
</tr>
</tbody>
</table>

IVS, Interventricular septum; PW, posterior wall; LVEDD, left ventricular end-diastolic diameter; FS, fractional shortening; SAM, systolic anterior motion of the anterior mitral leaflet; ΔP, pressure gradient; HR, heart rate; SBP, systolic blood pressure; DBP, diastolic blood pressure; RPP, rate pressure product; NS, not significant.

**Hemodynamics**

Heart rate, systolic and diastolic pressure, as well as rate pressure product (RPP) were comparable in the 3 groups. Under dipyridamole infusion RPP increased significantly after dipyridamole in controls (11520 ± 2124 vs 7424 ± 815, P < .01), in patients who had undergone surgical myectomy (9840 ± 2450 vs 7720 ± 850, P < .01) and in medically treated patients (10671 ± 1483 vs 8083 ± 1678, P < .01). There was no significant difference between RPP of the 3 groups after dipyridamole.

**MBF and CFR**

Global MBF at baseline was similar in controls (0.72 ± 0.20 mL/g/min) and operated patients (0.67 ± 0.15 mL/g/min) but higher in medically treated patients (0.89 ± 0.21 mL/g/min, P < .01 vs both). Dipyridamole induced a significant increase in MBF in controls (3.04 ± 1.00 mL/g/min, P < .0001 vs baseline) and in patients with hypertrophic cardiomyopathy (P < .005). However, the response was significantly reduced in operated patients (1.55 ± 0.39 mL/g/min) and medically treated patients (1.49 ± 0.47 mL/g/min, both P < .001 vs controls; Figure 1). This resulted in a global CFR of 3.87 ± 0.92 for controls, 2.31 ± 0.40 for operated patients (P < .001 vs controls), and 1.76 ± 0.58 for medically treated patients (P < .001 vs controls, P < .05 vs operated patients), respectively (Table 2).

Septal MBF was 0.90 ± 0.27 mL/g/min in controls, 0.68 ± 0.14 mL/g/min in operated patients (P < .05 vs controls), and 0.87 ± 0.18 mL/g/min in medically treated patients (P < .05 vs operated patients). Hypoemic MBF was significantly larger in controls (3.78 ± 1.67) than operated patients (1.54 ± 0.33, P < .001 vs controls) or medically treated patients (1.40 ± 0.45, P < .001 vs controls), respectively (Figure 1). Septal CFR was 4.19 ± 1.22 in controls, but significantly reduced in operated patients (2.26 ± 0.48,
and medically treated patients (1.65 vs 0.53; P < .001 vs controls). CFR was significantly higher in operated than medically treated patients (+37%, P < .05). Furthermore, the difference in CFR between the lateral free wall and the septum was larger in medically treated patients, namely 16% (P < .05 vs controls) compared with 7% in operated patients and -5% in controls (Figure 2).

**Influence of Outflow Tract Gradient on Maximal MBF, CFR, and Coronary Resistance**

In the medically treated group patients with outflow tract obstruction, maximal hyperemic MBF was significantly lower in septal (1.1 ± 0.3 mL/min/g vs 1.7 ± 0.4 mL/min/g; P < .05) and lateral segments (1.3 ± 0.3 mL/min/g vs 2.0 ± 0.6 mL/min/g; P < .05) compared with patients without outflow tract obstruction. Accordingly, in comparison with nonoperated patients gradient maximal hyperemic blood flow was significantly improved after myectomy in septal (1.6 ± 0.3 mL/min/g vs 1.2 ± 0.3 mL/min/g, P < .05) and lateral (1.8 ± 0.4 mL/min/g vs 1.4 ± 0.3 mL/min/g, P < .05) segments as was global CFR (Figure 3).

After myectomy minimal septal coronary resistance was significantly lower compared with nonoperated patients with outflow tract obstruction (57 ± 10 mm Hg/mL/min/g vs 79 ± 21 mm Hg/mL/min/g, P < .05), reaching values comparable to those found in patients without gradient (52 ± 5 mm Hg/mL/min/g). In controls minimal coronary resistance was significantly lower compared with either group of patients with HCM (34 ± 14 mm Hg/mL/min/g; P < .01).
TABLE 2. MBF and CFR measurements

<table>
<thead>
<tr>
<th></th>
<th>Controls</th>
<th></th>
<th>HCM-op</th>
<th></th>
<th>HCM-med</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>sep</td>
<td>lat</td>
<td>glob</td>
<td>sep</td>
<td>lat</td>
<td>glob</td>
</tr>
<tr>
<td>MBF—rest</td>
<td>0.90 ± 0.27</td>
<td>0.75 ± 0.28</td>
<td>0.72 ± 0.20</td>
<td>0.68 ± 0.14†</td>
<td>0.70 ± 0.16</td>
<td>0.67 ± 0.15</td>
</tr>
<tr>
<td>MBF—stress</td>
<td>3.78 ± 1.67</td>
<td>2.70 ± 0.82</td>
<td>3.04 ± 1.00</td>
<td>1.54 ± 0.335</td>
<td>1.70 ± 0.42†</td>
<td>1.55 ± 0.395</td>
</tr>
<tr>
<td>CFR</td>
<td>4.19 ± 1.22</td>
<td>3.81 ± 1.06</td>
<td>3.87 ± 0.92</td>
<td>2.26 ± 0.485</td>
<td>2.42 ± 0.49†</td>
<td>2.31 ± 0.405</td>
</tr>
</tbody>
</table>

Stress Pharmacologic stress with intravenous dipyridamole (0.56 mg/kg); sep, septal; lat, lateral; glob, global.
Values of MBF are given as mL/min/g; values of CFR are relative values.
*P < .05 vs controls.
†P < .01 vs controls.
§P < .001 vs controls.
‡P < .05 vs patients surgically treated for hypertrophic cardiomyopathy.

Discussion

The results of the present study confirm and extend previous observations of reduced CFR in HCM. In moderately symptomatic patients with HCM but without evidence for coronary artery disease we found a decreased CFR in agreement with earlier reports. Similarly to Camici and coworkers, CFR after dipyridamole stress was impaired in both hypertrophic and nonhypertrophic regions (ie, lateral free wall). This suggests a primary abnormality of the coronary bed as a cause for the blunted coronary flow response. Additionally, we found a relative reduction of septal CFR compared with the lateral wall in medically treated patients with HCM, supporting results from Grover-McKay and colleagues, who found significantly reduced [15N]-ammonia concentrations in the septum compared with the lateral wall of the left ventricle in HCM, while the opposite pattern is commonly found in normal volunteers. Our study is the first to investigate the impact of myectomy on regional myocardial perfusion. After surgical myectomy the observed difference between septal and lateral CFR was abolished despite the globally higher CFR in operated patients with HCM (Figure 2). Septal CFR was significantly higher in operated patients than in medically treated patients, although CFR in both groups remained significantly reduced compared with controls.

Determinants of CFR

CFR, defined as the ratio of near maximal to basal MBF, has been proposed as an indirect parameter to evaluate the function of the coronary circulation. It is an integrated measure of coronary flow through both the large epicardial coronary arteries and the microcirculation. A decrease in CFR can be due to the narrowing of epicardial coronary arteries—which was excluded in the present study, however—or to microvascular dysfunction. The latter can theoretically be caused by several mechanisms: (1) structural changes (ie, vascular remodeling with reduced lumen to wall ratio) or functional alterations involving neurohumoral factors; (2) small coronary arterioles may change their diameter as a result of autonomic innervation; (3) several extravascular mechanisms such as impaired diastolic relaxation, compression of the coronary arteries by high left ventricular filling pressures, and increased force of contraction (“milking”).

Mechanisms of Impaired CFR in HCM: Role of Myectomy

Although the precise mechanism of myocardial ischemia in individual patients with HCM is not clear, a number of pathophysiologic features have been found to cause a mismatch between oxygen supply and demand, including increased myocardial muscle mass, reduced capillary density, and “small vessel disease.” Recently, Schafer and coworkers documented presynaptic and postsynaptic autonomic dysfunction in HCM, with increased local catecholamine levels and down-regulation of myocardial beta-adrenergic receptors, which could contribute to microcirculatory dysregulation. Left ventricular diastolic dysfunction in HCM has the potential to cause myocardial ischemia probably by causing a maldistribution of transmyocardial blood flow, with a reduced subendocardial/subepicardial flow ratio after dipyridamole infusion. An outflow tract obstruction is associated with reduced maximal hyperemic flow. Myectomy may exert its beneficial effect on CFR by reducing extravascular compressive forces as a result of improved diastolic relaxation, reduced force of contraction, and, thus, reduced compression of the coronary arteries. These mechanisms may not be entirely limited to the septum and therefore may have some influence on global CFR, as evidenced by the higher global CFR in operated patients compared with medically treated patients without outflow tract obstruction.

CFR is defined as ratio of hyperemic to resting MBF and therefore may be susceptible to changes in the denominator (ie, the resting flow). Resting MBF was significantly lower in operated patients than medically treated HCM patients. However, the absolute hyperemic flow data (Table 2) further substantiate the CFR data, as operated patients had significantly higher hyperemic MBF compared with medically treated patients with obstruction.
Accordingly, septal coronary resistance, which was calculated to account for the driving pressure, was significantly higher in medically treated patients with outflow tract obstruction compared with those without obstruction and was significantly reduced after myectomy. This is illustrated best in Figure 2, showing that the difference in CFR between the lateral free wall and septum is maximal in subjects with gradient. Thus, our data confirm that myectomy improved vasodilator response in HCM, most probably due to the removal of the obstruction, although it cannot be ruled out that the 2 groups of patients with HCM did not start off at the same point in the disease process. It is, however, unlikely that the differences in MBF and CFR between operated patients and medically treated patients were already present before myectomy as the gradient seems to play the major role. Only measurements before and after myectomy in the same patients would provide definitive answers.

The beneficial effect of myectomy on CFR adds evidence that ischemia may indeed play an important role in the symptomatology and pathophysiology of HCM. The significantly reduced maximal MBF and CFR in patients with HCM suggests that ischemia may occur during high coronary flow and oxygen demand situations such as mental stress or physical activity. This is supported by the clinical finding that chest pain was less common in operated patients with HCM (none of the patients) than in medically treated patients with HCM (4 patients; chi-square test: \( P < .05 \)) and is in line with results of Cannon and coworkers,\(^1\) who reported a net lactate release in the coronary sinus during atrial pacing as a biochemical substrate for the simultaneous documented reversible defects in thallium-201 scanning.

**Study Limitations**

The large differences in wall thickness between patients with HCM and controls may affect the correct interpretation of the flow data due to differences in partial volume effects. To minimize these effects, we have corrected for partial volume effects by applying the method proposed by Hutchins and coworkers.\(^1\) The partial volume effect is extremely important in thin walls of less than 5 mm but less problematic in hypertrophic hearts with thick walls.\(^1\)

Patients with HCM were significantly older than the controls. This may have affected our results. In fact, Czernin et al\(^2\) found a gradual decline in CFR with aging. This was, however, primarily due to increased cardiac work and blood flow at rest rather than to an abnormal vasodilator capacity (since dipyridamole-induced hyperemic flow was not affected by aging). This does clearly not apply to our study, where baseline MBF was lower in patients with HCM despite their higher age. In addition, Uren and coworkers\(^3\) reported that MBF at rest and during hyperemia (and thus CFR) are roughly comparable up to 60 years of age. In the age group of 50 to 59 years, CFR tended to be maximal and even slightly higher than in the age group of 30 to 39 years (ie, our control group’s age). Thus, CFR would be expected to be higher in both HCM groups, rather than lower, compared with the younger controls, a fact that strengthens even further our results.

Differences in medical treatment between operated and medically treated HCM may represent a confounding factor for direct comparison of these groups. Indeed, 6 patients operated for HCM were treated with the calcium channel blocker verapamil, whereas only 3 of the medically treated patients were on this treatment. However, although verapamil has beneficial effects on the left ventricular relaxation\(^4\) and on transmural MBF distribution in HCM,\(^5\) it has no effect on total MBF as assessed with PET.\(^6\)

**Conclusions**

Global as well as septal CFR is reduced in patients with HCM. However, myectomy seems to have a beneficial effect on septal perfusion and CFR. Thus, ischemia may play an important role in the symptomatology and pathophysiology in HCM.

**References**

12. Muzik O, Beanlands RS, Hutchins GD, Mangner TJ, Nguyen N,


